Physician profile
Marc Posner
NPI 1114930211
$1,871.34
in general payments reported to CMS, 2019-2025
16 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $430 · 2021: $319 · 2022: $271 · 2023: $218 · 2024: $215 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $743.83 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $292.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.22 | 2021-2025 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $96.50 | 2020-2021 | |
| Abbott Laboratories | $95.37 | 2021-2022 | |
| Lilly USA, LLC | $43.97 | 2024 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $43.76 | 2021 | |
| Novo Nordisk INC | $28.86 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $24.38 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.33 | 2024 | Adstiladrin |
| Ultragenyx Pharmaceutical INC. | $21.27 | 2022 | |
| Mauna Kea Technologies, INC. | $19.71 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.79 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.13 | 2023 | Opsumit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $14.14 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.